Eskalith is a prescription medication that contains lithium carbonate as its active ingredient. It belongs to the mental health therapeutic class and is used primarily for mood stabilization. Eskalith is available in pill form, with each tablet containing 300 mg of lithium carbonate. In Hong Kong, lithium carbonate products are regulated by the Department of Health and require a prescription from a licensed healthcare professional.
Lithium carbonate exerts its mood-stabilizing effect through several biological pathways. It modulates neurotransmitter release, particularly glutamate and dopamine, which helps reduce excessive neuronal firing associated with mania. Lithium also influences intracellular signaling by inhibiting glycogen synthase kinase-3 (GSK-3) and altering the phosphatidyl-inositol cycle, leading to changes in gene expression that support neuronal resilience. These actions collectively contribute to a gradual improvement in mood, reduction of manic episodes, and prevention of relapse.
Eskalith is approved in Hong Kong for the treatment of bipolar disorder, including:
The medication may also be prescribed for schizoaffective disorder when mood symptoms predominate. Use is limited to adults and adolescents under specialist supervision, as recommended by local psychiatric guidelines.
Some clinicians prescribe lithium carbonate for conditions that are not formally approved but have supporting evidence:
Off-label use is not approved by the Hong Kong Department of Health. It requires careful medical supervision and an individualized risk-benefit assessment.
If any of these conditions apply, a healthcare provider should evaluate alternative treatments.
These effects are often dose-related and may improve with gradual titration.
If any severe symptoms appear, immediate medical attention is required.
Patients should disclose all medications, including over-the-counter drugs and supplements, before starting Eskalith.
Standard dosing: Treatment typically begins with one 300 mg tablet once daily, with gradual increases (e.g., to two tablets daily) based on serum lithium levels and clinical response.
Target serum range: 0.6 - 1.2 mEq/L for most patients; lower ranges may be used for maintenance.
Special populations:
Renal impairment: Start with 300 mg every other day or a reduced dose; monitor renal function every 1-2 weeks.
Elderly: Initiate with 300 mg once daily and titrate slowly.
Administration: Swallow the tablet whole with a full glass of water. It may be taken with or without food, but consistent timing each day helps maintain stable levels.
Missed dose: Take the missed tablet as soon as remembered unless it is near the time of the next scheduled dose; do not double-dose.
Overdose: Symptoms include severe tremor, confusion, vomiting, and cardiac arrhythmia. Seek emergency care; treatment may involve gastric lavage and intravenous hydration.
Discontinuation: Do not stop abruptly. Gradual tapering (e.g., reducing by 300 mg every 1-2 weeks) is recommended to avoid rebound mood instability.
Regular follow-up with a psychiatrist or prescribing clinician is essential for safe long-term use.
This article provides educational information about Eskalith and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes, you may travel with Eskalith, but keep the medication in its original packaging with a copy of the prescription. Carry it in your carry-on luggage to avoid temperature extremes and ensure it is easily accessible for customs checks.
Lithium and sodium share renal transport mechanisms. Low sodium intake can increase lithium reabsorption, raising blood levels and the risk of toxicity. Maintain a consistent, moderate sodium diet and inform your provider of any major dietary changes.
If you miss a dose and it is less than 12 hours until your next scheduled dose, skip the missed tablet and continue with your regular schedule. Do not double the dose to make up for the missed tablet.
Some patients report blurred vision or mild eye discomfort, especially at higher serum levels. Promptly report persistent visual symptoms to your clinician, as they may indicate toxicity.
The tablets contain lactose and magnesium stearate as inactive ingredients. Patients with lactose intolerance or specific excipient allergies should discuss alternatives with their pharmacist.
Herbal products such as St. John’s wort and ginseng can affect lithium metabolism or kidney function. Disclose all supplement use to your prescriber to evaluate potential interactions.
Lithium’s therapeutic effects often emerge gradually; many patients experience mood stabilization within 2-4 weeks, with full benefits sometimes taking several months of consistent therapy.
Routine urine testing is not required, but monitoring urine output and specific gravity can help detect early signs of nephrogenic diabetes insipidus, especially if you experience excessive thirst or urination.
Both lithium and valproate are first-line mood stabilizers, but they differ in mechanisms, side-effect profiles, and contraindications. Lithium is uniquely effective for preventing suicide and reducing manic relapse, whereas valproate may be preferred in patients with renal impairment or certain metabolic concerns. Clinical decisions should be individualized by a psychiatrist.
